New and Media

Media Release
March 18, 2021
Nationwide Children’s Hospital Affiliate Andelyn Biosciences Receives Significant Investment and Enters Into Strategic Partnership with Pall Corporation and Cytiva
May 28, 2019
Researchers identify a key regulatory protein implicated in Galgt2 overexpression and begin to elucidate its protective mechanism against muscular dystrophy.
April 19, 2019
Researchers recently published the long-term outcomes of patients who received the investigational drug AVXS-101 – an adeno-associated virus serotype 9 mediated gene replacement therapy.
November 16, 2018
The model aims to provide the basis for many future studies to bring therapeutic options to patients with FSHD.
July 24, 2018
Tests of NT-3 gene therapy on mouse models suggest potential to treat a host of muscle-wasting conditions.
April 2, 2018
Recent applications of adeno-associated virus (AAV) mediated gene therapy have focused mainly on correcting recessively inherited diseases. But what about dominantly inherited disorders? It looks like AAV could be a delivery mechanism for treating those genetic disorders, too.